Luye Pharma Group has partnered with DCH Auriga to exclusively distribute and market Seroquel® and Seroquel XR® in Singapore as part of a joint commitment to enhance mental health awareness. This partnership, formalized in Singapore, grants DCH Auriga rights to distribute the medications, used to treat schizophrenia and bipolar disorder, as endorsed by several global health guidelines.

Joint Mental Health Initiative to Address Public Health Concerns

As part of the “We Care About Mental Health” initiative, Luye Pharma and DCH Auriga are dedicated to supporting patients, healthcare providers, and systems in managing mental health. Recent surveys in Singapore reveal that 13.9% of adults experience mental health disorders, while the prevalence rates of bipolar disorder and schizophrenia are around 1.6% and 1%, respectively. Additionally, a stigma around mental health persists, with 68% of Singaporeans acknowledging its presence. The initiative focuses on raising awareness and reducing stigma while emphasizing prevention, early treatment, and counseling to mitigate mental health’s societal impact.

Strengthening Regional Reach and Advancing Healthcare Access

According to Andy Siow, APAC Regional Director of Luye Pharma, the partnership with DCH Auriga, a well-regarded Asian healthcare distributor, will improve access to critical CNS medications in Southeast Asia, with further plans to expand innovative treatment options across the region. Rajesh Sehgal, Vice President at DCH Auriga, expressed the company’s dedication to making quality healthcare more accessible and reducing social stigmas through the “We Care About Mental Health” campaign, further solidifying a foundation for expanded mental health care and support across Asia.